Journal of Immunology Research

Cancer Immunotherapy: Theory and Application


Publishing date
29 Dec 2017
Status
Published
Submission deadline
11 Aug 2017

Lead Editor

1National Institute on Aging, NIH, Baltimore, USA

2National Institute of Health Sciences, Tokyo, Japan

3Southeast University, Jiangsu Province, China

4Southeast University, Jiangsu Province, China


Cancer Immunotherapy: Theory and Application

Description

With the rapid increase in our understanding of the immune system, more and more small molecule, peptide, recombinant antibody, and vaccine, as well as cellular therapeutic modalities, are being applied to manipulate the immune response for cancer treatment. These immunotherapies have provided significant benefit for cancer, especially the application of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cell therapies.

To present the recent advances in the theory and application of cancer immunotherapy, we invite authors/investigators to contribute original research articles as well as review articles that will illustrate and stimulate the continuing effort to understand the implications of immunotherapy.

Potential topics include but are not limited to the following:

  • Advances in cancer immunotherapy theory
  • Immunomodulators for cancer
  • Immune enhancement therapies for cancer
  • Immune recovery for cancer
  • Genome editing for cancer immunotherapy
  • Cancer gene therapy of the immune system
  • Monoclonal antibodies for cancer immunotherapies
  • Immune checkpoint inhibitors
  • Dendritic cell-based pump-priming therapies
  • T cell adoptive transfer
  • Genetically engineered T cells therapies
  • Chimeric antigen receptor (CAR) T cell therapies
  • Vaccination for cancer
Journal of Immunology Research
 Journal metrics
Acceptance rate40%
Submission to final decision91 days
Acceptance to publication32 days
CiteScore3.330
Impact Factor3.404
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.